The FDA just approved a colon-cancer blood test. It could save people from spending hundreds of dollars on tests or relying on a colonoscopy alone.

50 million Americans due for colon cancer screening avoid it because they consider traditional tests so unpleasant. But now it can be as simple as a blood test. If you’re overdue for your colon cancer ...

INDIANAPOLIS (WISH) – This week, the United States Food and Drug Administration approved Guardant’s Shield blood test to screen for colon cancer in average-risk Americans 45 to 75 years old.

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

According to Cologuard, made by Wisconsin-based Exact Sciences, there are three primary reasons why you may receive a testing ...

After the fasting, the uncomfortable cleanse and a drowsy ride home, it's a relief to have your colonoscopy screening behind ...

Cases of colorectal cancer in younger adults are climbing worldwide, driven by lifestyle changes and inherited genetic risks.

WASHINGTON (DC News Now) — A new blood test may make it much easier and cheaper to screen for signs of colon cancer. Test manufacturer Guardant said the Food and Drug Administration (FDA) approved its ...

A recent study sheds light on why colorectal cancer is showing up more often in younger adults, pointing to a stiffer colon ...

FILE - A sign for the U.S. Food and Drug Administration is displayed outside their offices in Silver Spring, Md., Dec. 10, 2020. U.S. health regulators on Monday, July 29, 2024, approved a ...

The Food and Drug Administration (FDA) has recently approved a blood test that can assist in the primary detection of colorectal cancer. This test could assist with prompt detection and intervention ...

Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...